Urologic oncology

publication venue for

Corrigendum to definitive and sustained increase in prostate cancer metastases in the United States. 2022
Corrigendum to: National practice patterns for lymph node irradiation in 197,000 men receiving external beam radiotherapy for localized prostate cancer. 2019
Treatment of a radiation-induced rectal ulcer with hyperbaric oxygen therapy in a man with prostate cancer. 2006
Carcinosarcoma of the prostate with multiple metastases: case report and review of the literature. 2005
Benign fibrous histiocytoma: a rare finding on bone scan staging for prostate adenocarcinoma. 2003
Not all PI-RADS 3 lesions are the same: Higher rate of clinically significant prostate cancer among Black men on targeted biopsy in a diverse cohort.. 44. 2026
Incremental dose-response effect of age on mortality in non-seminoma testis cancer patients.. 44. 2026
Population-based utilization and survival of competing treatments for small renal masses: The growing role of thermal ablation.. 44. 2025
Long-term oncologic outcomes of metastatic clear-cell renal cell carcinoma after local therapy alone.. 44. 2025
Mini-subcostal incision technique for open radical nephrectomy: A practical alternative for complex renal masses.. 43. 2025
Incidence and prevention strategies for postprostate biopsy infections in the United States from 2012 to 2021.. 43. 2025
Prospective evaluation of comprehensive geriatric assessments in multidisciplinary bladder cancer care and implications for personalized vulnerability phenotyping. 2025
Barriers and facilitators of the application of precision medicine to the genitourinary cancer care pathway: Perspective from a low- and middle- income country in sub-Saharan Africa.. 42. 2024
Molecular and diffusion features for identification of clinically significant prostate cancer in PI-RADS 3 lesions.. 42. 2024
Clinical-imaging metrics for the diagnosis of prostate cancer in PI-RADS 3 lesions.. 42. 2024
The association between frailty, hypogonadism, and postoperative outcomes among men undergoing radical cystectomy. 2024
Long-term outcomes of pelvic-fascia sparing robotic-assisted radical prostatectomy versus standard technique: Superior urinary function and quality of life without compromising oncologic efficacy in a single-surgeon series.. 42. 2024
Performance of cognitive vs. image-guided fusion biopsy for detection of overall and clinically significant prostate cancer in a multiethnic population.. 42. 2023
Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer.. 41. 2023
Incidence and predictors of deep incisional and organ/space surgical site infection following radical cystectomy.. 41. 2023
Insurer coverage of prostate cancer biomarkers.. 41. 2023
Impact of surgical margin and extent of lymphadenectomy on oncologic outcomes in plasmacytoid urothelial carcinoma.. 41. 2023
Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer.. 40. 2022
A multidisciplinary approach to optimize primary prostate cancer biobanking.. 40. 2022
Novel nomograms to predict muscle invasion and lymph node metastasis in upper tract urothelial carcinoma.. 40. 2022
Does neoadjuvant chemotherapy diminish the sex disparity in bladder cancer survival after radical cystectomy?. 40. 2021
Risk factors and survival outcomes for upstaging after inguinal lymph node dissection for cN1 penile squamous cell carcinoma.. 39. 2021
Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma - An exploratory analysis.. 39. 2021
Comparative effectiveness analysis of first-line immunotherapy versus chemotherapy in metastatic urothelial carcinoma of the bladder.. 40. 2021
A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02.. 40. 2021
Phase II multi-center trial of optical coherence tomography as an adjunct to white light cystoscopy for intravesical real time imaging and staging of bladder cancer.. 39. 2021
Defining the index lesion for potential salvage partial or hemi-gland ablation after radiation therapy for localized prostate cancer.. 39. 2021
Tumor size and genomic risk in localized prostate cancer.. 39. 2021
Trends in the use of administrative databases in urologic oncology: 2000-2019.. 39. 2021
Racial and socioeconomic disparities in retroperitoneal lymph node dissection and survival in nonseminomatous germ cell tumor: A population-based study.. 39. 2021
Bupivacaine local anesthetic to decrease opioid requirements after radical cystectomy: Does formulation matter?. 39. 2020
A population-level analysis of nonsquamous penile cancer: The importance of histology.. 39. 2020
The role of surgical experience in patient selection, surgical quality, and outcomes in robot-assisted radical cystectomy.. 39. 2020
[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab.. 39. 2020
Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey.. 39. 2020
Preoperative nomogram predicting 12-year probability of metastatic renal cancer - evaluation in a contemporary cohort.. 38. 2020
Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?. 38. 2020
Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival.. 38. 2020
Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (¹⁷⁷Lu-J591) for metastatic castration-resistant prostate cancer.. 38. 2020
Development of robust artificial neural networks for prediction of 5-year survival in bladder cancer.. 39. 2020
Multicenter analysis of clinical and MRI characteristics associated with detecting clinically significant prostate cancer in PI-RADS (v2.0) category 3 lesions.. 38. 2020
Prognostic value of the SPOP mutant genomic subclass in prostate cancer.. 38. 2020
Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer.. 38. 2020
The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma.. 37. 2019
Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma.. 37. 2019
Definitive and sustained increase in prostate cancer metastases in the United States.. 37. 2019
The TERT locus genotypes of rs2736100-CC/CA and rs2736098-AA predict shorter survival in renal cell carcinoma.. 37. 2019
Perioperative, oncological and functional outcomes after robotic partial nephrectomy vs. cryoablation in the elderly: A propensity score matched analysis.. 37. 2019
National practice patterns for lymph node irradiation in 197,000 men receiving external beam radiotherapy for localized prostate cancer.. 37. 2019
Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy.. 37. 2018
Clinical value of cholinesterase in the prediction of biochemical recurrence after radical prostatectomy.. 36. 2018
Robotic versus open partial nephrectomy for highly complex renal masses: Comparison of perioperative, functional, and oncological outcomes.. 36. 2018
An evaluation of race, ethnicity, age, and sex-based representation in phase I to II renal cell carcinoma clinical trials in the United States.. 36. 2018
Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance.. 36. 2018
Effects of perineural invasion on biochemical recurrence and prostate cancer-specific survival in patients treated with definitive external beam radiotherapy.. 36. 2018
Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making tool.. 36. 2018
Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C.. 36. 2017
Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations.. 37. 2017
Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC).. 36. 2017
Concordance between patient-reported and physician-reported sexual function after radical prostatectomy.. 36. 2017
Demographic and socioeconomic predictors of treatment delays, pathologic stage, and survival among patients with penile cancer: A report from the National Cancer Database.. 36. 2017
Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes.. 36. 2017
Predictors of genitourinary malignancy in patients with asymptomatic microscopic hematuria.. 36. 2017
Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer.. 36. 2017
Population-based study of the incidence and survival for intraductal carcinoma of the prostate.. 35. 2017
Is restaging transurethral resection necessary in patients with non-muscle invasive bladder cancer and limited lamina propria invasion?. 35. 2017
Collecting duct carcinoma of the kidney: Disease characteristics and treatment outcomes from the National Cancer Database.. 35. 2017
Regionalization of radical cystectomy in the United States.. 35. 2017
Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.. 35. 2017
Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.. 35. 2017
Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma.. 35. 2017
Health status and use of partial nephrectomy in older adults with early-stage kidney cancer.. 35. 2016
Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma.. 35. 2016
External validation of the pathological nodal staging score in upper tract urothelial carcinoma: A population-based study.. 35. 2016
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.. 34. 2016
Technique and outcomes of bladder neck intussusception during robot-assisted laparoscopic prostatectomy: A parallel comparative trial.. 34. 2016
Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer.. 34. 2016
Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer.. 34. 2016
The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer.. 34. 2016
The difficulty in selecting patients for cytoreductive nephrectomy: An evaluation of previously described predictive models.. 35. 2016
Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis.. 34. 2016
Determinants of radical cystectomy operative time.. 34. 2016
Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide?. 34. 2016
GATA3 immunohistochemical expression in invasive urothelial carcinoma.. 34. 2016
Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy.. 34. 2016
The effect of delaying nephrectomy on oncologic outcomes in patients with renal tumors greater than 4cm.. 34. 2016
Outcome of genetic evaluation of patients with kidney cancer referred for suspected hereditary cancer syndromes.. 34. 2015
Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity.. 34. 2015
Salvage ablative therapy in prostate cancer: international multidisciplinary consensus on trial design.. 33. 2015
Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study.. 33. 2015
Validation of a frailty index in patients undergoing curative surgery for urologic malignancy and comparison with other risk stratification tools.. 33. 2015
Patterns of care for readmission after radical cystectomy in New York State and the effect of care fragmentation.. 33. 2015
Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging.. 33. 2015
BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study.. 33. 2015
The natural history of renal functional decline in patients undergoing surveillance in the DISSRM registry.. 33. 2015
The burden of skeletal-related events in patients with prostate cancer and bone metastasis.. 33. 2014
Validation of tertiary Gleason pattern 5 in Gleason score 7 prostate cancer as an independent predictor of biochemical recurrence and development of a prognostic model.. 33. 2014
The association between nerve sparing and a positive surgical margin during radical prostatectomy.. 33. 2014
Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).. 32. 2014
Initial experience with electronic tracking of specific tumor sites in men undergoing active surveillance of prostate cancer.. 32. 2014
Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly.. 33. 2014
Adherence to surveillance guidelines after radical cystectomy: a population-based analysis.. 32. 2014
Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer.. 32. 2014
Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States.. 32. 2014
The role of PTEN tumor suppressor pathway staining in carcinoma in situ of the bladder.. 32. 2014
Minimal changes in the systemic immune response after nephrectomy of localized renal masses.. 32. 2014
Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy.. 32. 2014
Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder.. 32. 2014
Optimal timing of early versus delayed adjuvant radiotherapy following radical prostatectomy for locally advanced prostate cancer.. 32. 2013
Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma.. 32. 2013
High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy.. 32. 2013
Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?. 32. 2013
Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordance.. 32. 2013
The impact of hospital volume, residency, and fellowship training on perioperative outcomes after radical prostatectomy.. 32. 2013
Combined therapeutic effects of adenoviral vector-mediated GLIPR1 gene therapy and radiotherapy in prostate and bladder cancer models.. 32. 2013
Long-term mortality in patients with germ cell tumors: effect of primary cancer site on cause of death.. 32. 2013
Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy.. 31. 2012
Indications for and anatomical extent of pelvic lymph node dissection for prostate cancer: practice patterns of uro-oncologists in North America.. 31. 2012
Morbidity and costs of salvage vs. primary radical prostatectomy in older men.. 31. 2012
Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma.. 31. 2011
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer.. 31. 2011
Attenuation of androgenic regulation by brefeldin A in androgen-responsive prostate cancer cells.. 31. 2011
Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.. 31. 2011
RET protein expression in papillary renal cell carcinoma.. 30. 2011
Clinical application of a 3D ultrasound-guided prostate biopsy system.. 29. 2011
The effect of minimally invasive and open radical prostatectomy surgeon volume.. 30. 2010
Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer.. 29. 2010
Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy?. 29. 2010
Analysis of gender differences in early perioperative complications following radical cystectomy at a tertiary cancer center using a standardized reporting methodology.. 28. 2010
What is the optimal management of high risk, clinically localized prostate cancer?. 28. 2010
The impact of Skp2 overexpression on recurrence-free survival following radical prostatectomy.. 29. 2009
Critical elements in fellowship training.. 27. 2009
Does the presence of hydronephrosis on preoperative axial CT imaging predict worse outcomes for patients undergoing nephroureterectomy for upper-tract urothelial carcinoma?. 29. 2008
Impact of radical prostatectomy positive surgical margins on fear of cancer recurrence: results from CaPSURE.. 28. 2008
Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model.. 27. 2008
A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate.. 27. 2008
Medical care cost of patients with prostate cancer.. 23. 2005
Franklin, Lavoisier, and Mesmer: origin of the controlled clinical trial.. 23. 2005
Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors.. 21. 2003
Mode of presentation of renal cell carcinoma provides prognostic information.. 7. 2002
A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men.. 7. 2002
Cytokine therapy in renal cell cancer.. 5. 2000
Timing of cystectomy for superficial bladder tumors.. 5. 2000
Carcinoid tumor of the kidney. The use of somatostatin receptor scintigraphy in diagnosis and management.. 5. 2000
Reversal of the low-affinity neurotrophin receptor stromal-epithelial expression pattern between benign and malignant human prostate.. 4. 1998
Updated concepts and treatment of carcinoma in situ.. 4. 1998
Neoadjuvant and adjuvant chemotherapy in locally advanced bladder cancer.. 3. 1997
Prediction of focal extracapsular extension at radical prostatectomy: Relative merit of transrectal ultrasound, endorectal magnetic resonance imaging, prostate specific antigen, prostate specific antigen density, and systematic biopsy.. 2. 1996
Selecting clinical research projects for the urologic oncologist.. 2. 1996
Uncertainty and outcome of invasive bladder tumors.. 2. 1996
Neoadjuvant M-VAC (methotrexate, vinblastine, adriamycin, and cisplatin) chemotherapy and bladder preservation for muscle-infiltrating transitional cell carcinoma of the bladder.. 1. 1995
Incorporating biomarker research in a real-world setting: challenges of a prophecy.. 32. 2014
Narrow band imaging cystoscopy.. 29. 2011
What has to happen before we report radical prostatectomy outcomes of individual surgeons to the public?. 29. 2010
Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma.". 2018
Commentary on "circulating angiostatin, bFGF, and Tie2/TEK levels and their prognostic impact in bladder cancer." Szarvas T, Jäger T, Laszlo V, Kramer G, Klingler HC, vom Dorp F, Romics I, Ergün S, Rübben H, Department of Urology, University of Duisburg-Essen, Germany.: J Urol 2012;80(3):13-8 [Epub 2012 May 17]. 2014
Commentary on "common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer." Garcia-Closas M, Rothman N, Figueroa JD, Prokunina-Olsson L, Han SS, Baris D, Jacobs EJ, Malats N, De Vivo I, Albanes D, Purdue MP, Sharma S, Fu YP, Kogevinas M, Wang Z, Tang W, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G Jr., Grubb R 3rd, Black A, Gapstur SM, Thun M, Diver WR, Weinstein SJ, Virtamo J, Hunter DJ, Caporaso N, Landi MT, Hutchinson A, Burdett L, Jacobs KB, Yeager M, Fraumeni JF Jr., Chanock SJ, Silverman DT, Chatterjee N, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.: Cancer Res 2013;73(7):2211-20 [Epub 2013 Mar 27]. 2014
Commentary on "tissue-specific mutagenesis by N-butyl-N-(4-hydroxybutyl) nitrosamine as the basis for urothelial cell carcinogenesis." He Z, Kosinska W, Zhao ZL, Wu XR, Guttenplan JB, Department of Basic Science, New York University Dental College, NY, USA.: Mutat Res 2012;742(1-2):92-5 [Epub 2011 Dec 4]. 2014
The new era of precision urobiome: RE: "Characterization of urinary microbiome in patients with bladder cancer: Results from a single-institution, feasibility study" by Chipollini et al. 2020
Re: Herr et al.: BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: A prospective cohort outcomes study (Urol Oncol 2015; 33: 108.el-108.e4). 2015
A window into new drug development for urologic oncology. Part II: Bench-to-bedside research improves survival in urologic cancer, and the discovery of better biomarkers can help predict patient response, toxicity, and resistance to therapy.. 33. 2015
A window into new drug development for urologic oncology. Part I: How bench-to-bedside research can result in approval.. 33. 2015
A medical oncologist's perspective on the treatment of patients with genitourinary malignancies.. 27. 2009
Training of a surgeon-scientist.. 27. 2009
Introduction to "Molecular drivers of prostate cancer development, progression, and resistance to therapy". 2018
A multidisciplinary approach for the management of earlier stage renal cell carcinoma. 2018
Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview. 2016
Enzalutamide: Development from bench to bedside. 2015
Biomarker development in the context of urologic cancers. 2015
Reprint of: The prostate cancer genome: Perspectives and potential. 2015
Sunitinib as a paradigm for tyrosine kinase inhibitor development for renal cell carcinoma. 2014
Prostate cancer biomarkers: an update. 2014
The prostate cancer genome: perspectives and potential. 2013
Environmental toxicology of testicular cancer. 2012
Optimal timing of radical cystectomy for patients with T1 bladder cancer. 2009
Optimizing outcomes at every stage of bladder cancer: do we practice it? 2009
Laparoscopic radical prostatectomy: contemporary comparison with open surgery. 2007
The use and abuse of data: nomograms and talking to patients about clinical medicine. 2007
Cell-surface targets for prostate cancer therapeutics. 2026
State of the Art: The Microbiome in Bladder Cancer. 2024
Randomized trials of PSA screening. 2024
Primary retroperitoneal lymph node dissection for clinical stage II seminoma: A systematic review and meta-analysis of safety and oncological effectiveness. 2024
A new era in the treatment of urothelial carcinoma. 2023
Antibody-drug conjugates for urothelial carcinoma. 2023
Targeting bladder cancer: A sex sensitive perspective in mutations and outcomes. 2023
Bladder preservation after neoadjuvant therapy - 2021 IBCN updates part 1. 2023
Implementation of a comprehensive prehabilitation program for patients undergoing radical cystectomy. 2022
Gene network profiling in muscle-invasive bladder cancer: A systematic review and meta-analysis. 2022
Bladder-sparing combination treatments for muscle-invasive bladder cancer: A plea for standardized assessment and definition of clinical trials endpoints. 2021
A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of urothelial cancer. 2021
A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of penile cancer. 2021
A 25-year review of advances in testicular cancer: Perspectives on evaluation, treatment, and future directions/challenges. 2021
Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand? 2021
Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma. 2021
Systemic therapy in bladder preservation. 2020
The value and limitations of urothelial bladder carcinoma molecular classifications to predict oncological outcomes and cancer treatment response: A systematic review and meta-analysis. 2020
Inguinal lymph node dissection in the era of minimally invasive surgical technology. 2020
Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis. 2019
Role of lymph node dissection in renal cell cancer. 2019
Novel biomarkers in bladder cancer. 2018
Second-line systemic therapy in metastatic renal-cell carcinoma: A review. 2017
Heterogeneity in renal cell carcinoma. 2017
Prostate cancer risk stratification with magnetic resonance imaging. 2016
Immunotherapy for genitourinary malignancies in the here and now! 2015
Pediatric and adolescent renal cell carcinoma. 2015
Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide. 2015
Salvage high-dose chemotherapy for germ cell tumors. 2015
Biomarkers for immunotherapy in genitourinary malignancies. 2015
Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer. 2015
Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. 2014
Highlights from the first symposium on upper tract urothelial carcinoma. 2014
Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. 2013
Target detection: magnetic resonance imaging-ultrasound fusion-guided prostate biopsy. 2013
Urine markers for detection and surveillance of bladder cancer. 2013
Prostate-specific membrane antigen-based imaging. 2012
Summary of the 6th Annual Bladder Cancer Think Tank: new directions in urologic research. 2012
Fibroblast growth factor receptor-3 in urothelial tumorigenesis. 2012
Radical prostatectomy: positive surgical margins matter. 2012
Current status of focal primary therapy for prostate cancer. 2012
Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting. 2012
Salvage therapies after radiation therapy. 2012
Fine-tuning robot-assisted radical prostatectomy planning with MRI. 2011
Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer. 2010
Statistical consideration for clinical biomarker research in bladder cancer. 2010
Do high-volume hospitals and surgeons provide better care in urologic oncology? 2009
Pathologic assessment and clinical significance of prostatic involvement by transitional cell carcinoma and prostate cancer. 2008
Low risk prostate cancer in men under age 65: the case for definitive treatment. 2007
Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis. 2006
Incorporating predictions of individual patient risk in clinical trials. 2004

VIVO Weill Cornell Medical College

Urologic oncology Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)